In probably a new drug scandal from China, self-proclaimed employees alleged that a Fosun unit faked production and testing records.

It was a U.S. drugmaker that first alerted the FDA that a valsartan API from a Chinese ingredient maker contained a a dangerous impurity.

China has withheld shipments of the H7N9 strain to the U.S. for research, according to The New York Times.

The Nasdaq-listed plasma specialist is raising $590 million via share issuance to fund business expansion plans and strategic acquisitions.

China is criminally prosecuting people and companies tied to Juxin Biotech where a plant explosion killed 10 people.

Korean biotech ViroMed has acquired a GMP-ready facility in San Diego, California, as its gene therapy nears the completion of phase 3 trials.

With Bristol-Myers' Opdivo sticker, the benchmark for prices of future immuno-oncology therapies in China is here.

An ongoing criminal trial in Korea alleges that Novartis used medical journals to funnel kickbacks to doctors.